According to filings with the U.S. Securities and Exchange Commission, GelMEDIX is raising up to $3,500,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Jeffrey Behrens played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About GelMEDIX
GelMEDIX Inc. is an early-stage biotechnology company committed to innovating the next generation of ocular and regenerative therapies through its proprietary hydrogel platform. GelMEDIXs programs are based upon its photo crosslinked hydrogels, originally developed by Prof. Nasim Annabi (UCLA) and Prof. Reza Dana (Mass Eye and Ear, Harvard Medical School). These hydrogels uniquely enable bioadhesion, tissue regeneration, tunable mechanics, and therapeutic loading across modalities from small molecules to cell and gene therapies. GelMEDIX is developing drug products for indications across the eye focused on cell-based therapies for vision restoration, intraocular sustained release of small molecules and peptides, and in situ forming bioadhesives.

To learn more about GelMEDIX, visit http://www.gelmedix.com/

Contact:
Jeffrey Behrens, Chief Executive Officer
941-228-8711
https://www.linkedin.com/in/jbehrens/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.